Kymera STAT6 Phase IIb data and BofA target reviewed
Kymera Therapeutics is advancing its STAT6 program toward Phase III, with Phase IIb atopic dermatitis data due by year-end. The roundup also notes BofA raised its price target to $144.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.